2022
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update. Endocrine Practice 2022, 28: 923-1049. PMID: 35963508, PMCID: PMC10200071, DOI: 10.1016/j.eprac.2022.08.002.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesEvidence-based recommendationsPractice guidelinesGlycemic targetsDiabetes mellitusComprehensive careCare plansEvidence-based clinical practice recommendationsEndocrinology Clinical Practice GuidelineNew evidence-based recommendationsLiterature searchManagement of prediabetesDiabetes care teamDiabetic kidney diseaseClinical practice recommendationsComprehensive care planType 1 diabetesAmerican AssociationCare of personsHealth care professionalsSecondary diabetesBariatric surgeryInsulin therapyClinical evidenceKidney diseaseOnce-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care 2022, 45: 1833-1840. PMID: 35679098, PMCID: PMC9346995, DOI: 10.2337/dc21-2275.Peer-Reviewed Original ResearchConceptsType 2 diabetesEfficacy end pointWeekly exenatideAdverse eventsPlacebo groupPrimary efficacy end pointSecondary efficacy end pointsEnd pointMetformin monotherapyTreatment of youthInsulin therapyWeek 24Pediatric patientsWeekly injectionsDaily injectionsGlycated hemoglobinCurrent treatmentExenatideBody weightDiabetesLiraglutideWeeksHemoglobinTreatmentBaseline
2017
Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin
Tamborlane WV, Pfeiffer KM, Brod M, Nikolajsen A, Sandberg A, Peters AL, Van Name M. Understanding bolus insulin dose timing: the characteristics and experiences of people with diabetes who take bolus insulin. Current Medical Research And Opinion 2017, 33: 639-645. PMID: 28008782, DOI: 10.1080/03007995.2016.1275937.Peer-Reviewed Original ResearchConceptsBolus insulinDose timingBolus insulin therapyPrevious weekType 2 diabetesExperiences of peopleInsulin therapyTreatment optionsDiabetes educationWeb-based surveyType 1DiabetesMajority of respondentsInsulinSelf-report surveyGeneralizability of findingsT2DT1DMealWeeksHypoglycemiaRespondentsTherapyBolusPotential bias
2016
Continuous Glucose Monitoring: A Consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology
Fonseca VA, Grunberger G, Anhalt H, Bailey TS, Blevins T, Garg SK, Handelsman Y, Hirsch IB, Orzeck EA, Roberts VL, Tamborlane W, Committee O. Continuous Glucose Monitoring: A Consensus Conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocrine Practice 2016, 22: 1008-1021. PMID: 27214060, DOI: 10.4158/ep161392.cs.Peer-Reviewed Original ResearchConceptsContinuous glucose monitoringAmerican CollegeCGM coverageClinical EndocrinologistsBenefits of CGMSensor-Augmented Pump TherapyClinical Endocrinologists ACEHealthcare resource utilizationIntensive insulin therapyHealth-related qualityType 1 diabetesManagement of diabetesAmerican AssociationAvailable CGM dataReal-world analysisChronic complicationsInsulin therapyDiabetes typeGlycemic controlPump therapyPatient understandingConsensus conferenceDiabetes managementHealth outcomesType 2
2015
The past, present, and future of basal insulins
Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes/Metabolism Research And Reviews 2015, 32: 478-496. PMID: 26509843, DOI: 10.1002/dmrr.2763.Peer-Reviewed Original ResearchConceptsInsulin glargine 100Basal insulinGlargine 100Glycemic controlUnits/mLNew insulin glargine 300Neutral protamine Hagedorn (NPH) insulinBasal insulin peglisproNew insulin productsSimilar glycemic controlGood glycemic controlInsulin glargine 300Type 2 diabetesDuration of actionInsulin delivery techniquesGlargine 300Insulin detemirInsulin therapyInsulin degludecNew insulinsPharmacodynamic profileInsulin secretionPharmacodynamic propertiesPrandial increaseFundamental therapyC‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry
Gregg B, Connor CG, Cheng P, Ruedy KJ, Beck RW, Kollman C, Schatz D, Cengiz E, Tamborlane WV, Klingensmith GJ, Lee JM, Consortium F. C‐peptide levels in pediatric type 2 diabetes in the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2015, 17: 274-280. PMID: 25940861, DOI: 10.1111/pedi.12280.Peer-Reviewed Original ResearchConceptsC-peptide levelsC-peptide measurementsLower body mass indexPediatric type 2 diabetesInsulin-treated patientsEndogenous insulin secretionPediatric diabetes centersC-peptide valuesBody mass indexType 2 diabetesT2D durationInsulin therapyClinical factorsDiabetes CenterClinic registryMass indexC-peptideInsulin secretionInsulin treatmentLarge cohortT2DMetabolic controlType 2Biologic dataRegistryImproved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes
Raz I, Bitton G, Feldman D, Alon T, Pfutzner A, Tamborlane WV. Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes. Journal Of Diabetes Science And Technology 2015, 9: 639-643. PMID: 25883166, PMCID: PMC4604546, DOI: 10.1177/1932296815578881.Peer-Reviewed Original ResearchConceptsRapid-acting insulin analoguesType 2 diabetesMeal tolerance testPlasma insulin levelsInsulin analoguesInsulin levelsGlucose excursionsInjection siteInsulin absorptionType 2 diabetic patientsPostmeal glucose excursionsStandardized liquid mealPostprandial glucose excursionsTime-action profilePostprandial glucose controlInsulin therapyDiabetic patientsGlucose controlLiquid mealOvernight fastInsulin aspartTolerance testPostprandial hyperglycemiaPremeal bolusesPremeal injectionsPresentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study
Kelsey MM, Geffner ME, Guandalini C, Pyle L, Tamborlane WV, Zeitler PS, White NH, Group F. Presentation and effectiveness of early treatment of type 2 diabetes in youth: lessons from the TODAY study. Pediatric Diabetes 2015, 17: 212-221. PMID: 25690268, PMCID: PMC4539288, DOI: 10.1111/pedi.12264.Peer-Reviewed Original ResearchConceptsType 2 diabetesDiabetes educationGlycemic controlRecent-onset type 2 diabetesLow-density lipoprotein cholesterolBiochemical parametersCardiometabolic risk factorsDiagnosis of T2DBody mass indexShort-term improvementStandardized diabetes educationInsulin discontinuationTarget HbA1cCommon comorbiditiesInsulin therapyLipoprotein cholesterolMedian hemoglobinBlood pressureMedian ageT2D cohortMass indexTreatment optionsRisk factorsEarly treatmentOutcome measures
2012
Insulin Therapy in Children and Adolescents
Tamborlane WV, Sikes KA. Insulin Therapy in Children and Adolescents. Endocrinology And Metabolism Clinics Of North America 2012, 41: 145-160. PMID: 22575411, DOI: 10.1016/j.ecl.2012.01.002.Peer-Reviewed Original ResearchConceptsMultiple daily injectionsContinuous insulin infusionInsulin therapyBasal-bolus therapyMainstay of treatmentInsulin replacement therapyType 2 diabetesType 1 diabetesDaily injectionsReplacement therapyAnalogue insulinInsulin infusionInsulin secretionBiosynthetic humanTherapyInsulin formulationsNormal patternDiabetesTreatmentChildrenAdolescentsInfusionAimMainstayInsulin
1985
Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes.
Simonson DC, Tamborlane WV, DeFronzo RA, Sherwin RS. Intensive insulin therapy reduces counterregulatory hormone responses to hypoglycemia in patients with type I diabetes. Annals Of Internal Medicine 1985, 103: 184-90. PMID: 3893253, DOI: 10.7326/0003-4819-103-2-184.Peer-Reviewed Original ResearchConceptsCounterregulatory hormone responsesPump treatmentHormone responseCounterregulatory hormone releaseInsulin pump treatmentPerception of hypoglycemiaIntensive insulin therapyIntensive insulin treatmentInsulin clamp techniqueType IBlood glucose levelsCounterregulatory hormonesGlucose counterregulationInsulin therapyHypoglycemic stimulusHypoglycemic episodesGlucagon releaseHealthy controlsInsulin treatmentHormone releaseStudy groupGlucose levelsHypoglycemic periodNormal controlsHypoglycemia